Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where G. Bertino is active.

Publication


Featured researches published by G. Bertino.


Alimentary Pharmacology & Therapeutics | 2017

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study

Giuseppe Cabibbo; Salvatore Petta; V. Calvaruso; Irene Cacciola; M.R. Cannavò; S. Madonia; M. Distefano; L. Larocca; T. Prestileo; Fabio Tinè; G. Bertino; Lydia Giannitrapani; F. Benanti; Anna Licata; I. Scalisi; Giovanni Mazzola; F. Cartabellotta; Nicola Alessi; Marco Barbara; M. Russello; G. Scifo; Giovanni Squadrito; Giovanni Raimondo; A. Craxì; V. Di Marco; C. Cammà

Data on HCV‐related hepatocellular carcinoma (HCC) early recurrence in patients whose HCC was previously cured, and subsequently treated by direct‐acting antivirals (DAAs), are equivocal.


European Journal of Internal Medicine | 2012

Current practice of chronic hepatitis B treatment in Southern Italy.

Tommaso Stroffolini; A. Spadaro; V. Di Marco; G. Scifo; M. Russello; Giuseppe Montalto; G. Bertino; L. Surace; B. Caroleo; G. Foti; V. Portelli; S. Madonia; M. Sapienza; L. Cosco; P. Frugiuele; A. Galdieri; N. Brandolino; R. Siciliano; Savino Bruno; P.L. Almasio

BACKGROUND Treatment choice for chronic HBV infection is a continuously evolving issue, with a wide range of options. We aimed to evaluate the current practice of HBV therapies in the real world in Southern Italy. METHODS A prospective study enrolling over a six month period (February-July 2010) all consecutive HBsAg positive subjects, never previously treated, referred to 16 liver units in two Southern Italy regions (Calabria and Sicily). RESULTS Out of 247 subjects evaluated, 116 (46.9%) had HBV-DNA undetectable or lower than 2000 UI/ml. There were 108 (43.7%) inactive carriers, 103 (41.7%) chronic hepatitis, and 36 (14.6%) liver cirrhosis. Antiviral treatment was planned in 94 (38.0%) patients (26 cases with Interferon or Pegylated Interferon and 68 with nucleos(t)ides analogues). As many as 49.5% of subjects with chronic hepatitis did not receive antiviral treatment. DISCUSSION The majority of chronic HBsAg carrier referring centres for evaluation were not considered suitable for antiviral treatment. Nucleos(t)ides analogues are the preferred first choice for therapy. A long-lasting period of observation may be needed to make appropriate therapeutic decisions in several cases.


Digestive and Liver Disease | 2017

Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs)

Giuseppe Cabibbo; Irene Cacciola; M.R. Cannavò; S. Madonia; V. Calvaruso; Salvatore Petta; M. Distefano; L. Larocca; T. Prestileo; Fabio Tinè; A. Digiacomo; G. Bertino; Lydia Giannitrapani; F. Benanti; A. Davì; Riccardo Volpes; I. Scalisi; C. Iacobello; Giovanni Mazzola; F. Cartabellotta; L. Guarneri; V. Portelli; A. Averna; M. Russello; G. Scifo; Giovanni Squadrito; Giovanni Raimondo; A. Craxì; V. Di Marco; C. Cammà


Journal of Hepatology | 2017

Non-invasive tools to ruling out large varices: RESIST-HCV vs. Baveno VI criteria in a large cohort of patients with HCV cirrhosis

V. Calvaruso; Irene Cacciola; Anna Licata; S. Madonia; R. Benigno; F. Bronte; Salvatore Petta; G. Malizia; G. Bertino; M. Di Stefano; Riccardo Volpes; A. Montineri; A. Di Giacomo; Giuseppe Alaimo; Bruno Cacopardo; L. Guarneri; I. Scalisi; Giovanni Mazzola; F. Cartabellotta; V. Portelli; M. Russello; Giovanni Squadrito; Giovanni Raimondo; A. Craxì; V. Di Marco


Digestive and Liver Disease | 2017

Efficacy of oral direct acting antivirals for treatment of advanced chronic hepatitis or compensated cirrhosis due to hepatitis C virus infection: The real-life experience of the Sicily registry

Irene Cacciola; Salvatore Petta; M. Distefano; M.R. Cannavò; A. Davì; S. Madonia; V. Calvaruso; L. Larocca; F. Di Lorenzo; A. Digiacomo; G. Bertino; Anna Licata; Federica Latteri; F. Benanti; Riccardo Volpes; L. Guarneri; A. Averna; I. Scalisi; C. Iacobello; Piero Colletti; F. Cartabellotta; V. Portelli; M. Russello; G. Scifo; Giovanni Squadrito; Giovanni Raimondo; A. Craxì; V. Di Marco


Journal of Hepatology | 2018

Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort

V. Calvaruso; Salvatore Petta; Irene Cacciola; Giuseppe Cabibbo; C. Fabio; M.A. Di Rosolini; A. Davì; M.R. Cannavò; M. Russello; M. Di Stefano; G. Scifo; F. Di Lorenzo; P. Tullio; L. Larocca; A. Montineri; G. Fuduli; A. Di Giacomo; M. Cannizzaro; S. Madonia; Anna Licata; G. Malizia; Giuseppe Alaimo; G. Bertino; Bruno Cacopardo; C. Iacobello; A. Averna; L. Guarneri; I. Scalisi; Giovanni Mazzola; Luigi Mondello


Digestive and Liver Disease | 2018

Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort

V. Calvaruso; Salvatore Petta; Irene Cacciola; Giuseppe Cabibbo; F. Cartabellotta; A. Di Rosolini; A. Davì; M.R. Cannavò; M. Russello; M. Distefano; G. Scifo; F. Di Lorenzo; T. Prestileo; L. La Rocca; A. Montineri; G. Fiduli; A. Digiacomo; M. Cannizzaro; S. Madonia; Anna Licata; G. Malizia; Giuseppe Alaimo; G. Bertino; Bruno Cacopardo; C. Iacobello; A. Averna; L. Guarneri; I. Scalisi; Giovanni Mazzola; Luigi Mondello


Journal of Hepatology | 2017

Risk of hepatocellular carcinoma recurrence in hepatitis C cirrhotic patients treated with direct acting antivirals

Giuseppe Cabibbo; Irene Cacciola; M.R. Cannavò; S. Madonia; V. Calvaruso; Salvatore Petta; M. Di Stefano; L. Larocca; T. Prestileo; Fabio Tinè; A. Digiacomo; G. Bertino; Lydia Giannitrapani; F. Benanti; A. Davì; Riccardo Volpes; L. Guarneri; A. Averna; I. Scalisi; C. Iacobello; Giovanni Mazzola; F. Cartabellotta; V. Portelli; M. Russello; G. Scifo; Giovanni Squadrito; Giovanni Raimondo; A. Craxì; V. Di Marco; C. Cammà


Journal of Hepatology | 2017

Efficacy of oral Direct Acting Antivirals for the treatment of chronic hepatitis/cirhhosis due to hepatitis C virus infection: the real-life experience of the Sicily Registry

Irene Cacciola; Salvatore Petta; M. Di Stefano; M.R. Cannavò; A. Davì; S. Madonia; V. Calvaruso; Luca La Rocca; F. Di Lorenzo; A. Digiacomo; G. Bertino; Anna Licata; F. Benanti; Riccardo Volpes; L. Guarneri; A. Averna; I. Scalisi; C. Iacobello; Piero Colletti; F. Cartabellotta; V. Portelli; M. Russello; G. Scifo; Giovanni Squadrito; Giovanni Raimondo; A. Craxì; V. Di Marco


Journal of Hepatology | 2017

Efficacy and safety of 12-week DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort

S. Madonia; V. Calvaruso; R. Filomia; M.R. Cannavò; M. Di Stefano; M. Russello; A. Davì; G. Scifo; Riccardo Volpes; A. Montineri; R. Ficalora; G. Malizia; A. Digiacomo; G. Bertino; Giuseppe Alaimo; Anna Licata; Bruno Cacopardo; A. Averna; L. Guarneri; I. Scalisi; Piero Colletti; F. Cartabellotta; F. Savalli; M. Cannizzaro; Giovanni Raimondo; A. Craxì; V. Di Marco

Collaboration


Dive into the G. Bertino's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G. Scifo

University of Palermo

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Craxì

University of Palermo

View shared research outputs
Top Co-Authors

Avatar

A. Davì

University of Palermo

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge